Patients with lymph node metastasis showed a higher expression of NUCB2/NESF-1 compared to those without lymph node metastasis (49.5%, vs. 36.6%, p = 0.043). Here, NUCB2 is linked to metastatic malignant neoplasm in the lymph nodes.